Gelonghui October 16th | Nanjing Pharmaceutical (600713.SH) announced that the Shanghai Stock Exchange Listing Committee held the 24th review meeting of the year on October 16, 2024, to review the company's application to issue convertible corporate bonds to unspecified entities. According to the review results of the meeting, the company's application to issue convertible corporate bonds to unspecified entities complies with issuance conditions, listing conditions, and disclosure requirements.
南京医药(600713.SH)：发行可转债申请获得上交所上市审核委员会审议通过
Nanjing Pharmaceutical (600713.SH): The application for issuing convertible bonds has been approved by the review committee of the Shanghai Stock Exchange.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated